Back to search results

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

IsraelActive Not RecruitingPHASE1

Conditions

Diffuse Large B-Cell Lymphoma · Chronic Lymphocytic Leukemia · B Cell Malignancies · Non-Hodgkin's Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California Los Angeles Medical Center /ID# 246357, Los Angeles, California, United States

  • Yale University School of Medicine /ID# 259081, New Haven, Connecticut, United States

  • Mount Sinai Medical Center-Miami Beach /ID# 248251, Miami Beach, Florida, United States

  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 250113, Fort Wayne, Indiana, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 259872, Indianapolis, Indiana, United States

  • Tulane Cancer Center Clinic /ID# 249586, New Orleans, Louisiana, United States

  • START Midwest /ID# 252359, Grand Rapids, Michigan, United States

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 245459, New York, New York, United States

  • Atrium Health Levine Cancer Institute /ID# 246363, Charlotte, North Carolina, United States

  • University Of Cincinnati Medical Center /ID# 262288, Cincinnati, Ohio, United States

  • University of Texas MD Anderson Cancer Center /ID# 245463, Houston, Texas, United States

  • University of Utah Health Hospital /ID# 259924, Salt Lake City, Utah, United States

  • Northwest Medical Specialties - Tacoma /ID# 260376, Tacoma, Washington, United States

  • Bankstown-Lidcombe Hospital /ID# 260191, Bankstown, New South Wales, Australia

  • Orange Health Service /ID# 260473, Orange, New South Wales, Australia

  • Monash Health - Monash Medical Centre /ID# 246366, Clayton, Victoria, Australia

  • The Alfred Hospital /ID# 248592, Melbourne, Victoria, Australia

  • UZ Gent /ID# 246462, Ghent, Oost-Vlaanderen, Belgium

  • Universitair Ziekenhuis Leuven /ID# 246461, Leuven, Vlaams-Brabant, Belgium

  • CHRU Lille - Hopital Claude Huriez /ID# 252054, Lille, Nord, France

  • IUCT Oncopole /ID# 259409, Toulouse, Occitanie, France

  • Charite Universitaetsmedizin Berlin Campus Virchow-Klinikum /ID# 252062, Berlin, Germany

  • Shamir Medical Center /ID# 257711, Beer Ya'akov, Central District, Israel

  • Rabin Medical Center. /ID# 257665, Petah Tikva, Central District, Israel

  • Hadassah Medical Center-Hebrew University /ID# 251441, Jerusalem, Jerusalem, Israel

  • The Chaim Sheba Medical Center /ID# 251442, Ramat Gan, Tel Aviv, Israel

  • Seoul National University Hospital /ID# 266340, Seoul, Seoul Teugbyeolsi, South Korea

  • Asan Medical Center /ID# 266341, Seoul, Seoul Teugbyeolsi, South Korea

  • Samsung Medical Center /ID# 266415, Seoul, Seoul Teugbyeolsi, South Korea

  • Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 246537, L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Vall de Hebron /ID# 245475, Barcelona, Spain

  • Hospital Clinic de Barcelona /ID# 246543, Barcelona, Spain

  • Hospital Universitario Ramon y Cajal /ID# 246540, Madrid, Spain

  • Hospital Universitario 12 de Octubre /ID# 246538, Madrid, Spain

  • China Medical University Hospital /ID# 266414, Taichung, Taiwan

  • National Taiwan University Hospital /ID# 266343, Taipei, Taiwan

  • Leeds Teaching Hospitals NHS Trust /ID# 245470, Leeds, West Yorkshire, United Kingdom

  • The Royal Marsden NHS Foundation Trust /ID# 250324, London, United Kingdom

  • The Christie Hospital /ID# 250325, Manchester, United Kingdom

Study leads

  • ABBVIE INC.

    Study Director

    AbbVie

View source on ClinicalTrials.gov(opens in a new tab)